Vaishnavi Muthu

Publications by Year

Research Areas

Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Gastric Cancer Management and Outcomes, Cancer Genomics and Diagnostics, Tuberculosis Research and Epidemiology

Most-Cited Works

• → Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases(2022)42 cited
• → Bitten by a bug or a bag? Transfusion‐transmitted dengue: a rare complication in the bleeding surgical patient(2015)41 cited
• → Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre(2020)29 cited
• → Low-Dose Nivolumab in Renal Cell Carcinoma: A Real-World Experience(2021)26 cited
• → Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia(2022)21 cited
• → Atypical Response Patterns in Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors—Navigating the Radiologic Potpourri(2021)14 cited
• → Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases.(2021)8 cited
• → ASO Visual Abstract: Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases(2022)2 cited
• → Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia.(2020)2 cited
• → P2.04-36 Immune Checkpoint Inhibition for Non-Small Cell Lung Cancer (NSCLC) in Patients with Pulmonary Tuberculosis or Hepatitis B(2019)1 cited